The Fudan University Shanghai Cancer Center, also called the Shanghai Cancer Hospital, is a teaching hospital affiliated with the Shanghai Medical College of Fudan University. Founded in 1931, it is the first cancer specialty hospital in China. It is rated Grade 3, Class A.

There are 1,100 beds in Fudan University Shanghai Cancer Center.

During the past decade, Fudan University Shanghai Cancer Center conducted 674 clinical trials. In the 10-year time frame, 674 clinical trials started and 65 clinical trials were completed, i.e. on average, 9.6% percent of trials that started reached the finish line to date. In the past 5 years, 432 clinical trials started and 49 clinical trials were completed. i.e. 11.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fudan University Shanghai Cancer Center" #1 sponsor was "Fudan University" with 373 trials, followed by "Hoffmann-La Roche" with 57 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 30 trials sponsored, "BeiGene" with 22 trials sponsored and "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 22 trials sponsored. Other sponsors include 356 different institutions and companies that sponsored additional 173 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fudan University Shanghai Cancer Center" #1 collaborator was "Fudan University" with 37 trials as a collaborator, "Zhejiang Cancer Hospital" with 15 trials as a collaborator, "RenJi Hospital" with 11 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 8 trials as a collaborator and "Shanghai Zhongshan Hospital" with 8 trials as a collaborator. Other collaborators include 476 different institutions and companies that were collaborators in the rest 266 trials.

According to Clinical.Site data, the most researched conditions in "Fudan University Shanghai Cancer Center" are "Breast Cancer" (106 trials), "Colorectal Cancer" (26 trials), "Gastric Cancer" (24 trials), "Esophageal Squamous Cell Carcinoma" (23 trials) and "Metastatic Breast Cancer" (22 trials). Many other conditions were trialed in "Fudan University Shanghai Cancer Center" in a lesser frequency.

Most popular intervention types in "Fudan University Shanghai Cancer Center" are "Drug" (694 trials), "Radiation" (83 trials), "Procedure" (60 trials), "Other" (42 trials) and "Biological" (37 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (76 trials), "Paclitaxel" (34 trials), "Capecitabine" (28 trials), "Carboplatin" (28 trials) and "Cisplatin" (27 trials). Other intervention names were less common.

The vast majority of trials in "Fudan University Shanghai Cancer Center" are 644 trials for "All" genders, 185 trials for "Female" genders and 34 trials for "Male" genders.

Currently, there are 427 active trials in "Fudan University Shanghai Cancer Center". 26 are not yet recruiting, 279 are recruiting, 114 are Active, not recruiting, and 8 are Enrolling by invitation. In total, there were 185 completed trials in Fudan University Shanghai Cancer Center, 1 suspended trials, and 25 terminated clinical trials to date.

Out of the total trials that were conducted in Fudan University Shanghai Cancer Center, 138 "Phase 1" clinical trials were conducted, 399 "Phase 2" clinical trials and 250 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 65 trials that are defined as “Not Applicable".

Fudan University Shanghai Cancer Center has several departments that took part in Clinical trials: "Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University" - 7 trials